



INVESTOR IN PEOPLE

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

REC'D 18 DEC 2003

WIPO


PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Dated

5 December 2003

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
South Wales
NP9 1RH

1. Your reference PWC/P34098GB

2. Patent application number

(The Patent Office will fill in this part)

0226374.7

12 NOV 2002

3. Full name, address and postcode of the or of each applicant (underline all surnames)

3998 564003

Patents ADP number (if you know it)

Isis Innovation Limited
Ewert House
Ewert Place
Summertown
Oxford OX2 7SG, GB

If the applicant is a corporate body, give the country/state of its incorporation

United Kingdom

4. Title of the invention

Ligands

5. Name of your agent (if you have one)

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

Kilburn & Strode
20 Red Lion Street
London
WC1R 4PJ

Patents ADP number (if you know it)

125001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is not named as an applicant, or
 - c) any named applicant is a corporate body.
- See note (d))

YES

Patents Form 1/77

- Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description

27

Claim(s)

2

Abstract

-

Drawing(s)

4 + 4 SW

10. If you are also filing any of the following, state how many against each item.

Priority documents

-

Translations of priority documents

-

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

-

Request for preliminary examination and search (Patents Form 9/77)

-

Request for substantive examination (Patents Form 10/77)

-

Any other documents (please specify)

-

11.

I/We request the grant of a patent on the basis of this application.

Signature

Date 12/11/02

12. Name and daytime telephone number of person to contact in the United Kingdom

Mr Paul W. Chapman
Tel: 020 7539 4200

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

LIGANDS

The present invention relates to aptamers that bind to viral envelope proteins, more specifically aptamers that bind to the envelope glycoprotein gp120 of HIV.

Viruses can evolve strategies to resist current anti-viral drugs and the selection pressures of humoral and cellular adaptive immunity. For example, HIV-1, R5 strains, which use the CCR5 co-receptor for entry and are the dominant viral phenotype for HIV-1 transmission and AIDS pathogenesis, are relatively resistant to neutralisation by antibodies.

While current anti-viral drugs have prolonged the quality of life for many HIV-1+ individuals, they do not eliminate the virus from an infected individual (1, 2). The failure of candidate vaccine antigens based on recombinant HIV-1 surface envelope glycoprotein, gp120, to elicit antibodies that neutralise HIV-1 primary isolates (PIs), and the rapid emergence of drug-resistant HIV-1 strains have encouraged continued efforts to find novel antiretroviral agents with modalities different from those currently in use. One approach is to target the stage at which virus infects host cells. The entry of HIV-1 into target cells, its cellular tropism and the pathogenesis of AIDS are largely determined by the virion surface glycoprotein, gp120, particularly the sequence of the hypervariable loops (3-5). For example, variations in the external portions of the sequence of gp120 determine the cellular tropism of the virus by governing the interaction with chemokine receptors such as CCR5 and CXCR4 (6). Strains that depend on the former co-receptor, known as R5 strains, are preferentially transmitted from host to host (7), dominate the asymptomatic stage of infection (8, 9), and are sufficient to cause AIDS (10).

There are two major phenotypic classes of HIV-1, namely those that infect immortalised lymphoblastoid cells lines preferentially (T-tropic) and those that infect primary macrophages (M-tropic). M-tropic strains are predominant at all stages of infection *in vivo* and are particularly difficult to neutralise with antibodies.

Aptamers are ligands comprising typically 20 to 120 nucleic acids and can be used to define functionally conserved sites on the surface of proteins. The effect of aptamer-virus binding can be to prevent the infection of cells if the binding site is essential for infection. In the case of HIV, the present drugs on the market all act on intracellular targets, such as reverse transcriptase and protease) to prevent replication of the virus. Therefore these drugs can only be used to treat cells that are already infected. As drug-resistant viruses are now appearing it is becoming more important to identify new drugs for antiviral therapy. A treatment that prevented the infection of the cell would be highly desirable. This could be done by targeting the envelope glycoprotein of the virus, with suitable aptamers.

Exemplified aptamers of the present invention are able to bind to the gp120 glycoprotein of a range of strains of HIV-1 and neutralise their infectivity by many orders of magnitude. In the case of the clinically relevant strains that infect only primary leukocytes, the degree of neutralisation we see with aptamers is unprecedented compared with antibodies or any other specific ligand.

Aptamers that bind to the HIV gp-120 molecules have been described previously (Sayer *et al* (2002) Biochem Biophys Res Commun 293 924-31). However these aptamers were raised against gp120 from a T-tropic strain and were not capable of neutralising the virus. Therefore they are not likely to be

useful clinically. The aptamers of the present invention bind to M-tropic gp120, and are capable of neutralising the virus.

Thus in a first aspect the present invention provides a nucleic acid molecule
5 capable of binding to an envelope glycoprotein of an enveloped virus, and neutralising said virus.

The virus is preferably HIV, more preferably HIV-1. In one preferred embodiment the glycoprotein is gp120.

10 In one particular preferred embodiment the aptamer is selected from one of those listed in Table 1.

The term "enveloped" virus is one well known to those skilled in the art and refers to those families of viruses which possess a viral envelope, e.g.
15 retroviruses.

Herein, the term "neutralising" refers to neutralising/reducing infectivity of said enveloped virus, preferably by at least one or of magnitude, more preferably by several orders of magnitude.

20

In a second aspect the present invention provides a method for screening for potential therapeutic targets utilising the aptamers of the invention. As the effect of aptamer-virus binding is to prevent the infection of cells, it is possible to identify small molecules that compete with the aptamer for virus binding.

25

These molecules would bind to the same functionally conserved site on the virus, so inhibit virus infection, and therefore be useful in the development of anti-viral therapeutics. The use of aptamers in high-throughput screens has been described (Green and Janjic (2001) *Biotechniques* 30 1094-6, 1098, 1100 passim.)

The aptamers of the present invention can themselves be used as therapeutic molecules. Thus in a third aspect the present invention provides a pharmaceutical composition comprising at least one nucleic acid molecule of the invention, optionally together with one or more pharmaceutically acceptable carriers, diluents or excipients.

The nucleic acid can be either RNA or DNA, single or double stranded. Typically the nucleic acid molecules are 20-120 nucleotides in length. The nucleotides that form the nucleic acid can be chemically modified to increase the stability of the molecule, to improve its bioavailability or to confer additional activity on it. For example the pyrimidine bases may be modified at the 6 or 8 positions, and purine bases at the 5 position with CH₃ or halogens such as I, Br or Cl. Modifications on pyrimidines bases also include 2 NH₃, O⁶-CH₃, N⁶-CH₃ and N²-CH₃. Modifications at the 2' position are sugar modifications and include typically a NH₂, F or OCH₃ group. Modifications can also include 3' and 5' modifications such as capping.

Aptamers can be prepared by methods well known to those skilled in the art, for example by solid phase synthesis (Ogilvie, K.K., et al (1988) Proc, Natl, Acad. Sci. U.S.A 85 (16) p5764-8; Scaringe, S.A (2000) Methods Enzymol 317 p 3-18) or *in vitro* transcription (Heidenreich, O., W. Peiken and F. Eckstein (1993) Faseb J. 7(1) p90-6.)

The compositions of the invention may be adapted for administration by any appropriate route, for example by the oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous, intrathecal, intraocular, or intradermal) route. Such formulations may be prepared by any method known in

the art of pharmacy, for example by bringing into association the active ingredient with the carrier(s) or excipient(s).

5 Pharmaceutical formulations adapted for oral administration may be presented as discrete units such as capsules or tablets; powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; edible foams or whips; or oil-in-water liquid emulsions or water-in-oil liquid emulsions.

10 Pharmaceutical formulations adapted for transdermal administration may be presented as discrete patches intended to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. For example, the active ingredient may be delivered from the patch by iontophoresis as generally described in *Pharmaceutical Research*, 3(6), 318 (1986).

15 Pharmaceutical formulations adapted for topical administration may be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils.

20 For applications to the eye or other external tissues, for example the mouth and skin, the formulations are preferably applied as a topical ointment or cream. When formulated in an ointment, the active ingredient may be employed with either a paraffinic or a water-miscible ointment base. Alternatively, the active ingredient may be formulated in a cream with an oil-in-water cream base or a water-in-oil base.

25

Pharmaceutical formulations adapted for topical administration to the eye include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent.

Pharmaceutical formulations adapted for topical administration in the mouth include lozenges, pastilles and mouth washes.

5 Pharmaceutical formulations adapted for rectal administration may be presented as suppositories or enemas.

10 Pharmaceutical formulations adapted for nasal administration wherein the carrier is a solid include a coarse powder having a particle size for example in the range 20 to 500 microns which is administered in the manner in which snuff is taken, i.e. by rapid inhalation through the nasal passage from a container of the powder held close up to the nose. Suitable formulations wherein the carrier is a liquid, for administration as a nasal spray or as nasal drops, include aqueous or oil solutions of the active ingredient.

15 Pharmaceutical formulations adapted for administration by inhalation include fine particle dusts or mists which may be generated by means of various types of metered dose pressurised aerosols, nebulizers or insufflators.

20 Pharmaceutical formulations adapted for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations.

25 Pharmaceutical formulations adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain antioxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example

water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets.

- 5 Preferred unit dosage formulations are those containing a daily dose or sub-dose, as herein above recited, or an appropriate fraction thereof, of an active ingredient.

10 It should be understood that in addition to the ingredients particularly mentioned above, the formulations may also include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavouring agents.

In an additional aspect the present invention provides:

- 15 (i) the use of at least one nucleic acid molecule of the present invention in the manufacture of a medicament for use in the treatment of HIV infection; and
- (ii) a method for the treatment of HIV infection comprising administering an effective amount of at least one nucleic acid molecule of the invention to a subject.

20

The present invention will now be described in more detail with reference to the following examples, which should not be construed as in any way limiting the scope of the invention.

25 The examples refer to the figures:

Figure 1: Isolation of aptamers that bind the gp120 of an R5 tropic HIV-1_{Ba-L}. (A) After four rounds of selection, the polyclonal pool of 2F-RNA showed strong and specific binding to HIV-1_{Ba-L} gp120, and binding was enriched by a

further selection cycle. (B) Aptamer B19 bound gp120 from both HIV-1_{Ba-L} and HIV-1_{MB}. An aptamer concentration of 100nM was used in all the experiments.

Figure 2: Neutralisation of R5 HIV-1 strains by monoclonal aptamers. Virus was titrated by limiting dilution in PBMC in the presence of the 100nM of the aptamers indicated. No reduction infectivity is indicated by open columns, between 10 and 100-fold reduction of infectivity by shaded columns, $10^3 - 10^4$ -fold reduction of infectivity by hatched columns and $>10^4$ -fold reduction of infectivity by solid columns. A and B show neutralisation of HIV-1_{Ba-L}, the strain from which the aptamers were raised. Seventeen aptamers neutralised the virus by 3-4 \log_{10} IU/ml, and two aptamers B4 and B84 inhibited HIV-1_{Ba-L} entry by more than 4 \log_{10} IU/ml. (C) Aptamer B4 inhibited HIV-1_{Ba-L} entry in a concentration-dependent manner, and with an IC_{50} value of less than 1nM. (D) Five of the aptamers tested so far also cross-neutralised another R5 strain, HIV-1_{ADA}.

Figure 3: Failure of HIV-1_{Ba-L} to escape neutralisation by aptamer B4. (A) The predicted sequence of gp120 deduced from sequencing env amplified from four break-through clones of virus following five rounds of selection and passage of HIV-1_{Ba-L} in PBMC in the presence of aptamer B4. The sequences are aligned to that of the inoculum virus (NIH510*) and the database sequence of HIV-1_{Ba-L} (M68893). Dashes represent unsequenced portions. "X" indicates an uncertain residue. Dots indicate identity with the database sequence. (B) Complete neutralisation of clonal HIV-1_{Ba-L}-derived breakthrough stock with 100 nM of aptamer B4 in human PBMC as assayed by the $TCID_{50}$. (C) Graphical depiction of the $TCID_{50}$ data as statistically analysed with the ID_{50} software, showing neutralisation of HIV-1_{Ba-L} breakthrough clone by more than 4 \log_{10} IU/ml, compared to control aptamer. The results are representative of all the clones in that all the four break-through clones were equally neutralised.

Figure 4: Effect of aptamer B4 on the binding of mAbs to gp120. Recombinant Ba-L gp120 was captured on the surface of a microtitre plate by polyclonal antibody. If indicated, the bound gp120 was then allowed to interact with soluble CD4. The bound gp120 or gp120/CD4 complex was then incubated with varying concentrations of aptamer B4 in triplicate. The gp120/aptamer or gp120/CD4/aptamer complexes were then incubated with the anti-gp120 mAbs indicated at a concentration previously determined to be in the linear detection range of each. Bound mAb was then detected using an anti-Ig-HRP system. The results are displayed as a % reduction from the aptamer-free control value \pm standard error.

Example

15 Materials and Methods

Virus stocks

All HIV-1 strains used in this study were obtained through the AIDS Research and Reference Reagent Program, NIAID, NIH, Bethesda, USA. HIV-1_{Ba-L} was contributed by S. Gartner, M Popovic and R. Gallo (19), HIV-1_{ADA} by H. Gendelman (20), and HIV-1_{MB} by R. Gallo (21)

Monoclonal Antibodies

25 Anti-gp120 monoclonal antibodies 17b (22), & 48d (23) 2G12 (24) IgG1 b12 (25), and polyclonal human HIV-Ig (26) were obtained from the NIH AIDS Reagent Program (www.aidsreagent.org). mAb 19b was kindly provided by James Robinson, Department of Pediatrics, University of Connecticut, Farmington, Connecticut, 06030, USA. Anti-gp120-CD4 complex monoclonal

antibody CG10 (27) and recombinant CD4-Ig were obtained from the NIBSC Centralised Facility for AIDS Reagents. Anti-FLAG M2 and anti-mouse IgG HRP monoclonal antibodies were obtained from Sigma.

5 Cells

Spodoptera frugiperda Sf9s cells were kindly provided by Ian Jones (Reading University, UK).

Human leukocytes were obtained from buffy coat fractions supplied by Bristol Hospital Services, through the Oxford National Blood Services.

Oligonucleotides (listed 5' - 3')

The "Library" oligonucleotide had the composition,
 15 AATTAACCCTCACTAAAGGGAACTGTTGTGAGTCTCATGTCGAA
 (N)₄₉TTGAGCGTCTAGTCTTGTCT.

"5' primer"

was: AATTAACCCTCACTAAAGGGAACTGTTGTGAGTCTCATGTCGAA

20 "3' primer" was:

TAATACGACTCACTATAGGGAGACAAGACTAGACGCTCAA.

"Env₆₃₀₉₊" primer was AGCAGAAGACAGTGGC.

"Env₈₀₂₃₋" primer was TAGTGCTTCCTGCTGCTCC.

6

25 Expression of HIV-1_{Ba-L} gp120

Sf9s cells were cultured at 28°C, in SF 900 II serum-free insect medium (GibcoBRL) in suspension culture below 1×10^6 cell/ml. Sf9s cells were transfected with a mixture of 500 ng p2BaC-gp120 (28) encoding HIV-1_{Ba-L}

SU glycoprotein (gp120) and linearised pAcBAK6 (Invitrogen) to generate recombinant virus following standard methods (29). Cells were infected at an m.o.i. of 5 and incubated for 4 days at 28°C, at which time secretion of gp120 into the medium was optimal. gp120 was purified from clarified culture supernatants using anti-FLAG M2 (Sigma) affinity chromatography and fractions were evaluated by SDS-PAGE and western blotting. Protein was further purified by FPLC gel filtration using Superdex 200 HR10/30 (Pharmacia) to exclude high order aggregates and quantified using BCA protein assay kit (Pierce, Chester, UK) according to manufacturer's instructions.

In vitro transcription

225 pmol of DNA template was added to a final 500 µl transcription reaction comprising 1 mM 2'F UTP, 1mM 2'F CTP (TriLink, USA), 1mM GTP, 1mM ATP (Amersham-Pharmacia), 40 mM Tris-Cl, pH 7.5, 6 mM MgCl₂, 5 mM DTT, 1 mM spermidine and 1500 units of T7 RNA polymerase (New England BioLabs) and incubated at 37°C for 16h. Transcription was terminated by addition of 1 unit RNase-free DNase I (Sigma) per ng of DNA template used, and the reaction was incubated for 15-30 min. at 37°C, followed by phenol/chloroform extraction. The RNA was precipitated using ethanol, redissolved in water, separated from low Mr contaminants using a Sephadex-G50 nick spin column (Pharmacia-Amersham) and quantified by determination of A₂₆₀. RNA was refolded by heating in water to 95°C for 3 min and then cooling to room temperature for 10 min, at which temperature 1/5 volume of 5x HBS buffer (final concentration, 10mM HEPES, pH 7.4, 150mM NaCl, 1mM CaCl₂, 1mM MgCl₂, 2.7mM KCl) was added, incubation continued at room temperature for 5 min.

In vitro selection of aptamers

A BIAcore (Stevenage, UK) 2000 biosensor instrument was used. 20 000 RU of HIV-1Ba-L gp120 was directly coupled to the carboxymethylated dextran surface of CM5 biosensor chips (research grade; BIAcore) using amine coupling through lysine residues following a standard protocol (30). RNA was prepared as described above in HBS. For the first round of selection, 20 µg of the RNA pool (a theoretical diversity of $\approx 10^{14}$ molecules) was injected at 1 µl/min at 37°C over the flow cell in which the gp120 was immobilised. Non-specifically bound RNA was removed by injecting 100 µl of the HBS buffer at 5 µl/min. Bound RNA was eluted with 100 µl of 7 M urea at 5 µl/min, and was deproteinised by extraction with phenol/chloroform and then precipitated with ethanol. Recovered RNA was reverse-transcribed to cDNA and PCR-amplified using the 3' and 5' primers described under slightly mutagenic conditions. The RNA: protein ratio was increased by a factor of about 4 each round to increase the stringency of selection. At every selection round the RNA was pre-cleared against at least two uncoupled sensor chip flow cells to serve as controls, and also to avoid the inadvertent selection of aptamers that might bind the chip matrix.

Analysis of aptamer-gp120 interaction by SPR biosensor

Affinity measurements were performed at 37°C. 5000–7500 RU of HIV-1 gp120 was covalently immobilised on the chip as described above. Aptamer or control nucleic acids were prepared at a range of concentrations (5 nM–3 200 nM), injected at 5 µl/min (KININJECT procedure) and allowed to dissociate over 60 min. The ligand was regenerated by injecting 1–5 µl of freshly prepared 100 mM NaOH to dissociate any RNA that was still bound without affecting the ability of gp120 to bind soluble CD4. Data were analysed using

the BIAevaluation 3.0 (BIAcore) and GraphPad Prism 3.00 (GraphPad software Inc., USA) and the K_D was calculated from the ratio of k_{off} and k_{on} .

Cultivation of human peripheral blood mononuclear cells (PBMC)

5

These were isolated by Ficoll-Hypaque (Pharmacia-Amersham, UK) density gradient centrifugation from heparinised buffy coats of normal, HIV-negative donors. The diluted, autologous plasma was saved, heat-inactivated and clarified to provide autologous serum (AS) supplement for leukocyte culture.

10

The PBMC were washed 6 times in PBS (Sigma) at 4°C and were essentially free of platelets and granulocytes. PBMC cultures were cultivated without mitogen activation and without the addition of specific growth factors such as IL-2, and were maintained in X-VIVO-10 (Bio-Whittaker) containing 2% AS. This procedure produces a slowly proliferating mixed culture of lymphocytes and macrophages that in our hands supports a higher level of replication of primary isolates than mitogen-treated, cytokine-supplemented cultures.

15

Virus infectivity and neutralisation assays

20

Day 7 PBMC were infected with serially diluted virus that had been incubated with 100 nM of anti-gp120 monoclonal aptamer or control aptamer, SA19 (17). Eight replicates were used at each 10-fold dilution. After 16 hours post infection the medium containing virus inoculum and aptamer was replaced with fresh culture medium. Cultures were maintained for 14 days before preparing DNA for LTR-PCR as described previously (31).

25

Selection for aptamer escape mutants

To attempt to generate aptamer B4 break-through variants, day 7 human PBMC (107) were infected with HIV-1Ba-L (105 IU), previously incubated with aptamer B4 (1nM). Samples of cell supernatant were collected every other day, until cytopathic effects were exhibited. The sample with the highest infectious titer was used to infect freshly differentiated PBMC in the absence of aptamer, in order to amplify virus to approximately 105 IU/ml. Four further cycles of selection and amplification were done following the same protocol, each selection using increasing concentrations of aptamer B4 (i.e. 5; 15; 50 and 100 nM). After the final round of selection, virus was cloned by limiting dilution in fresh PBMC. The *env* gene was PCR- amplified from virus-positive wells using the Env₆₃₀₉₊ and Env₈₀₂₃₋ primer pair and the high fidelity PCR system kit (Roche, Germany). The *env* gene of original seed HIV- 1Ba- L virus was similarly obtained.

Binding site mapping by antibody inhibition

This was done by competitive ELISA largely as previously described (32) with modifications as follows. Briefly, gp120 was captured in an Immulon II ELISA plate (Dynatech Ltd) using D7324 anti-gp120 COOH peptide antiserum (Aalto Bioreagents Plc.) After washing, bound gp120 was incubated with either 50µl of HBS buffer or 10 µM soluble human CD4 in HBS buffer for 1 hour at room temperature. The plate was washed, and 50µl of aptamer B4 was added at a range of concentrations, in triplicate, in HBS binding buffer for 1 hour. Anti-gp120 mAbs were added at a concentration previously determined to be within the linear range. After washing, bound antibody was detected using the ABC Elite amplification kit (Vector).

Results

Selection of aptamers against HIV-1_{Ba-L} gp120

We selected 2'-fluoropyrimidine-containing RNA (2'-F-RNA) aptamers against the gp120 of the R5 strain, HIV-1_{Ba-L}. The target protein was produced as previously described (28) and selection of aptamers was done using a modification of the SELEX protocol (33, 34) in which the target was immobilised on a BIAcore biosensor chip and enrichment was based on the slow dissociation rate of aptamers from target (Figure 1A). We used 2'-F-RNA aptamers because they are not only resistant to nucleases, but also widen the spectrum of potential tertiary conformations (16), and give rise to more compact and rigid ligands with higher affinities compared to unmodified RNA or NH₂-substituted RNA aptamers (35).

Immobilised gp120 initially bound less than 0.1% of the applied RNA, but this rose to 1.5% at round 2, 16% at round 3, 60% at round 4 and 75% at round 5. The PCR amplified DNA pool from the fifth round of selection was TA cloned. Each clone was screened by BIAcore analysis and those that bound the gp120 with high affinity (K_d 5-100 nM) as determined by BIAcore analysis, were found to belong to at least 25 distinct sequence families (Table 1). Although 15 most of the monoclonal aptamers bound selectively to HIV-1_{Ba-L} gp120, some, such as B19, showed significant binding to the gp120 derived from HIV-1_{IIIB}, an X4 virus (Figure 1C). Taken together these data imply that a large number of different sequences can fold to give gp120- binding aptamers, and that some of these aptamers might recognise a site on gp120 that is structurally conserved between these two R5 and X4 strains.

Neutralisation of HIV-1 by Aptamers

Antibodies elicited during natural infection with HIV-1 are generally poorly neutralising, and are generated late in infection (36). Moreover, monoclonal antibodies (mAbs) that recognise epitopes presented in the form of isolated gp120 usually do not bind the same epitope in the context of the assembled virion (37). This underlies the relative resistance of HIV-1 to neutralisation by mAbs, which is particularly pronounced in primary isolates. In this study we therefore asked whether the aptamers isolated against HIV-1Ba-L gp120 could prevent or limit HIV-1 infectivity of target cells. Using an end-point dilution and PCR-based TCID₅₀ assay (31, 38), we showed that 25 of the 27 aptamer clones assayed neutralised homologous HIV-1Ba-L in PBMC (Figure 2A and B). Most of these aptamers neutralised HIV-1Ba-L by more than 1000-fold, and one aptamer (B4) neutralised the virus by about 5 log₁₀. B4 inhibited HIV-1Ba-L entry with a 50% inhibition concentration (IC₅₀) value of less than 1nM in human PBMC (Figure 2C). All HIV-1Ba-L neutralising aptamers tested so far, including B4, also cross-neutralised another R5 strain, HIV-1_{ADA}, (Figure 2D). The gp120 of these two strains is only 84% identical and they show differences in the degree of their macrophage tropism (38). Therefore the ability of at least five aptamers to neutralise at least two HIV-1 strains suggests that they might recognise functionally important sites on gp120 that are conserved between at least the R5 members of this clade B sub-type.

HIV-1_{Ba-L} does not mutate to escape neutralisation by aptamer B4

25

HIV-1 mutates readily during infection in vivo in response to selection pressures, thereby propagating variants that can escape immune recognition and become resistant to anti-viral drugs (39). It has recently been shown that mutants of HIV-1 can resist the inhibitory effects of a CCR5 antagonist without

resorting to the use of alternative co-receptors (40) and the possibility that similar escape variants might have increased virulence raises concerns about the use of such drugs (41). We therefore tested whether HIV-1Ba-L could mutate to escape neutralisation by aptamer B4 by selecting for variants that could grow in human PBMC after challenge with the aptamer, as described in the Methods. Following selection through five cycles of progressively increasing aptamer concentration, four break-through clones of virus were isolated. The gp120-encoding portion of the env gene was determined for each clone and 25 compared with that of the parental virus (Figure 3A). We observed that the parental sequence diverges from that in the database by 1.9 %, though it is more closely related to that of the official Ba-L sequence than to that of any other HIV-1 strain in the database (analysis not shown). All four break-through clones had several additional amino acid substitutions in gp120, including in the putative neutralisation epitope at the V3 loop tip. We then tested whether these mutations had conferred resistance to aptamer B4 neutralisation by expanding the HIV-1_{Ba-L}-derived clones, followed by re-challenging the expanded virus with aptamer B4 and infection of human PBMC. Aptamer B4 neutralised all the break-through clones by up to 10⁵-fold (Figures 3B and 3C), implying that the mutations did not confer any selective advantage to HIV-1Ba-L. These data suggest that aptamer B4 might bind to a region of the gp120 that is critical to HIV-1_{Ba-L} function and therefore unable to mutate without detrimental effects to the virus.

Binding of aptamer B4 to gp120 affects the conserved CCR5-binding surface

A likely mechanism of neutralisation by aptamer was by inhibition of virus-receptor interaction, however, using SPR biosensor analysis, we found that B4 did not interfere with the binding of sCD4 to monomeric, immobilised gp120. We next tested whether B4 would interfere with the binding of monoclonal

antibodies whose epitopes had been previously mapped on gp120. The mAbs we chose were all neutralising as we hypothesised that B4 was likely to bind close to a conserved neutralisation epitope, rather than to a non-neutralising epitope. Of the ten mAbs tested, only one, 17b, was convincingly inhibited by aptamer in the absence of CD4 (see Figure 4A). The level of inhibition was significant but only 50% at the highest concentration of aptamer, suggesting that either the two molecules bound to spatially related but distinct surfaces or that the binding of B4 produced a subtle allosteric change in the epitope of 17b, reducing the level of antibody binding without abolishing it. The 17b epitope is partially obscured from antibody in the absence of CD4-binding by the V1 and V2 hypervariable loops of gp120 (23, 42) and overlaps with the binding site for the virus' major co-receptors, CCR5 and CXCR4 (43). The binding of a second antibody, 48d, which like 17b maps to the "CD4i" epitope, was inhibited by high concentrations of aptamer in the absence of CD4 but by nanomolar concentrations in the presence of CD4 (see Figure 4b). A third CD4i-binding antibody, CG10, was not inhibited by aptamer B4 at all.

Discussion

We present a novel strategy for identifying conserved regions of the envelope of primary HIV-1 isolates that could be targeted by potentially therapeutic agents. The small size and biophysical properties of aptamers have enabled us to target conserved sites on HIV-1 gp120 whose ligation produced highly efficient neutralisation of infectivity. Studies on the structure of gp120 complexes derived from HIV strains of differing co-receptor utilisation indicate that, although the surface loops of gp120 are of variable sequence and variable topology, the core of the protein, containing the principal receptor-interacting surfaces, is remarkably conserved in tertiary structure (12). Quaternary interactions between variable surface loops of gp120 monomers seem to have

evolved to enable the virus to escape from neutralisation by antibody but, critically, expose the conserved core of gp120 to interference by smaller ligands, such as aptamers.

5 Two properties of aptamer neutralisation deserve particular comment: potency and resistance to escape. The ability of an aptamer like B4 to reduce the infectivity of R5 virus is remarkable when compared with the most potent antibodies, such as IgG1-b12 and 2G12. These antibodies typically reduce infectivity of R5 strains by a single order of magnitude at concentrations of
10 approximately 300 nM (44) whereas, at 100 nM, aptamer B4 reduces infectivity by more than four orders of magnitude. Even at the highest concentrations practicable, specific neutralisation of PI HIV-1 by antibody rarely exceeds two orders of magnitude. Secondly, antibody-mediated neutralisation is rapidly overcome by virus evolution both in vitro (45) and in
15 vivo (46).

Other therapeutic strategies designed to interfere with HIV-entry include gp41-disrupting peptide analogs (47-49) and small-molecule ligands of CCR5 (40). The most promising, such as C34 (50) and T-20 (51) have IC50 values almost
20 comparable to the aptamers described here (~2nM). However, virus variants, resistant to inhibition by T-20 peptide, have now been identified in clinical trials (52).

Our results give some clues to the mechanism of neutralisation by aptamer.
25 Aptamer B4 did not interfere with the interaction between CD4 and gp120, nor the binding of antibodies whose epitopes on gp120 comprise the V3 loop, the V1V2 loops and the carbohydrate on the "silent" face. The ability of potently neutralising aptamer B4 to partially inhibit binding of mAbs 17b and 48d suggests that the mechanism of neutralisation may be by interfering with the

interaction of gp120 with its co-receptor, CCR5. In the absence of binding of CD4 to gp120, the 17b/48d epitopes are partially occluded on monomeric gp120 and fully occluded on functional, trimeric gp120, ensuring that it is only exposed to the antiviral effects of the humoral immune response very transiently during infection, if at all. In contrast, perhaps because of its smaller size or biophysical properties, aptamer B4 binds to its neutralisation site in the absence of CD4 binding. The CD4-dependent binding of antibody 48d to gp120 was more potently inhibited by aptamer B4 in the presence of CD4, implying that the access of aptamer B4 to the 48d epitope may be partially blocked on uncomplexed gp120. Intriguingly, we found that CG10, a third antibody that maps to the "CD4i" region, was not inhibited by aptamer B4 at all. This is consistent with the location of its epitope closest to the base of the V1V2 loops, and therefore the most occluded of these three epitopes (15, 53). Taken together with the evidence that the B4 binding site is highly conserved, this suggests that, as we had hoped, the aptamer approach has identified a more circumscribed and functionally important neutralisation target on gp120 than has been possible previously using antibodies.

References

1. Finzi, D., Blankson, J., Siliciano, J. D., Margolick, J. B., Chadwick, K., Pierson, T., Smith, K., Lisziewicz, J., Lori, F., Flexner, C., Quinn, T. C., Chaisson, R. E., Rosenberg, E., Walker, B., Gange, S., Gallant, J. & Siliciano, R. F. (1999) *Nat Med* 5, 512-7.
2. Piot, P., Bartos, M., Ghys, P. D., Walker, N. & Schwartlander, B. (2001) *Nature* 410, 968-73.
3. Chesebro, B., Nishio, J., Perryman, S., Cann, A., O'Brien, W., Chen, I. S. & Wehrly, K. (1991) *J Virol* 65, 5782-9.
4. Mondor, I., Moulard, M., Ugolini, S., Klasse, P. J., Hoxie, J., Amara, A., Delaunay, T., Wyatt, R., Sodroski, J. & Sattentau, Q. J. (1998) *Virology* 248, 394-405.
5. Chavda, S. C., Griffin, P., Han-Liu, Z., Keys, B., Vekony, M. A. & Cann, A. J. (1994) *J Gen Virol* 75 (Pt 11), 3249-53.
6. Berger, E. A., Doms, R. W., Fenyo, E. M., Korber, B. T., Littman, D. R., Moore, J. P., Sattentau, Q. J., Schuitemaker, H., Sodroski, J. & Weiss, R. A. (1998) *Nature* 391, 240.
7. Samson, M., Libert, F., Doranz, B. J., Rucker, J., Liesnard, C., Farber, C. M., Saragosti, S., Lapoumeroulie, C., Cognaux, J., Forceille, C., Muyldermans, G., Verhofstede, C., Burtonboy, G., Georges, M., Imai, T., Rana, S., Yi, Y., Smyth, R. J., Collman, R. G., Doms, R. W., Vassart, G. & Parmentier, M. (1996) *Nature* 382, 722-5.
8. Gendelman, H. E., Orenstein, J. M., Baca, L. M., Weiser, B., Burger, H., Kalter, D. C. & Meltzer, M. S. (1989) *Aids* 3, 475-95.
9. Ping, L. H., Nelson, J. A., Hoffman, I. F., Schock, J., Lamers, S. L., Goodman, M., Vernazza, P., Kazembe, P., Maida, M., Zimba, D., Goodenow, M. M., Eron, J. J., Jr., Fiscus, S. A., Cohen, M. S. & Swanstrom, R. (1999) *J Virol* 73, 6271-81.
10. Mosier, D. & Sieburg, H. (1994) *Immunol Today* 15, 332-9.

11. Kwong, P. D., Wyatt, R., Robinson, J., Sweet, R. W., Sodroski, J. & Hendrickson, W. A.
(1998) *Nature* 393, 648-59. 25
12. Kwong, P. D., Wyatt, R., Majeed, S., Robinson, J., Sweet, R. W., Sodroski, J. & Hendrickson, W. A. (2000) *Structure Fold Des* 8, 1329-39.
13. Cordonnier, A., Montagnier, L. & Emerman, M. (1989) *Nature* 340, 571-4.
14. Kowalski, M., Potz, J., Basiripour, L., Dorfman, T., Goh, W. C., Terwilliger, E., Dayton, A., Rosen, C., Haseltine, W. & Sodroski, J. (1987) *Science* 237, 1351-5. 30
15. Rizzuto, C. D., Wyatt, R., Hernandez-Ramos, N., Sun, Y., Kwong, P. D., Hendrickson, W. A. & Sodroski, J. (1998) *Science* 280, 1949-53.
16. Kraus, E., James, W. & Barclay, A. N. (1998) *J Immunol* 160, 5209-12.
17. Tahiri-Alaoui, A., Frigotto, L., Manville, N., Ibrahim, J., Romby, P. & James, W. (2002) *Nucleic Acids Research* 30, 1-9. 35
18. Sayer, N., Ibrahim, J., Turner, K., Tahiri-Alaoui, A. & James, W. (2002) *Biochem Biophys Res Comm* in press.
19. Gartner, S., Markovits, P., Markovitz, D. M., Betts, R. F. & Popovic, M. (1986) *Jama* 256, 2365-71.
20. Gendelman, H. E., Orenstein, J. M., Martin, M. A., Ferrua, C., Mitra, R., Phipps, T., Wahl, L. A., Lane, H. C., Fauci, A. S., Burke, D. S. & et al. (1988) *J Exp Med* 167, 1428-41.
21. Barre-Sinoussi, F., Chermann, J. C., Rey, F., Nugeyre, M. T., Chamaret, S., Gruest, J., Dauguet, C., Axler-Blin, C., Vezinet-Brun, F., Rouzioux, C., Rozenbaum, W. & Montagnier, L. (1983) *Science* 220, 868-71.
22. Sullivan, N., Sun, Y., Sattentau, Q., Thali, M., Wu, D., Denisova, G., Gershoni, J., Robinson, J., Moore, J. & Sodroski, J. (1998) *J Virol* 72, 4694-703.

23. Thali, M., Moore, J. P., Furman, C., Charles, M., Ho, D. D., Robinson, J. & Sodroski, J. (1993) *J Virol* 67, 3978-88.
24. Buchacher, A., Predl, R., Strutzenberger, K., Steinfellner, W., Trkola, A., Purtscher, M., Gruber, G., Tauer, C., Steindl, F., Jungbauer, A. & et al. (1994)
5 *AIDS Res Hum Retroviruses* 10, 359-69.
25. Burton, D. R., Barbas, C. F., 3rd, Persson, M. A., Koenig, S., Chanock, R. M. & Lerner, R. A. (1991) *Proc Natl Acad Sci U S A* 88, 10134-7.
26. Prince, A. M., Reesink, H., Pascual, D., Horowitz, B., Hewlett, I., Murthy, K. K., Cobb, K. E. & Eichberg, J. W. (1991) *AIDS Res Hum Retroviruses* 7,
10 971-3.
27. Gershoni, J. M., Denisova, G., Raviv, D., Smorodinsky, N. I. & Buyaner, D. (1993) *Faseb J* 7, 1185-7.
28. Lin, C. L., Sewell, A. K., Gao, G. F., Whelan, K. T., Phillips, R. E. & Austyn, J. M. (2000) *J Exp Med* 192, 587-94.
29. King, L. & Possee, R. (1992) *The Baculovirus expression system : a laboratory guide* (Chapman & Hall, London).
30. Karlsson, R., Michaelsson, A. & Mattsson, L. (1991) *J Immunol Methods* 145, 229-40.
31. Collin, M., Herbein, G., Montaner, L. & Gordon, S. (1993) *Res Virol* 144,
20 13-9.
32. Moore, J. P., McKeating, J. A., Jones, I. M., Stephens, P. E., Clements, G., Thomson, S. & Weiss, R. A. (1990) *Aids* 4, 307-15.
33. Ellington, A. D. & Szostak, J. W. (1990) *Nature* 346, 818-22.
34. Fitzwater, T. & Polisky, B. (1996) *Methods Enzymol* 267, 275-301.
35. Pagratis, N. C., Bell, C., Chang, Y. F., Jennings, S., Fitzwater, T., Jellinek, D. & Dang, C. (1997) *Nat Biotechnol* 15, 68-73.
36. Pilgrim, A. K., Pantaleo, G., Cohen, O. J., Fink, L. M., Zhou, J. Y., Zhou, J. T., Bolognesi, D. P., Fauci, A. S. & Montefiori, D. C. (1997) *J Infect Dis* 176, 924-32.

37. Moore, J. P. & Ho, D. D. (1995) *Aids* 9, S117-36.
 38. Collin, M., Illei, P., James, W. & Gordon, S. (1994) *J Gen Virol* 75, 1597-1603.
 39. Borrow, P., Lewicki, H., Wei, X., Horwitz, M. S., Pfeffer, N., Meyers, H.,
5 Nelson, J. A., Gairin, J. E., Hahn, B. H., Oldstone, M. B. & Shaw, G. M.
(1997) *Nat Med* 3, 205-11.
 40. Trkola, A., Kuhmann, S. E., Strizki, J. M., Maxwell, E., Ketas, T., Morgan,
T., Pugach, P., Xu, S., Wojcik, L., Tagat, J., Palani, A., Shapiro, S., Clader, J.
W., McCombie, S., Reyes, G. R., Baroudy, B. M. & Moore, J. P. (2002) *Proc*
10 *Natl Acad Sci U S A* 99, 395-400.
 41. Michael, N. L. & Moore, J. P. (1999) *Nat Med* 5, 740-2.
 42. Wyatt, R., Moore, J., Accola, M., Desjardin, E., Robinson, J. & Sodroski, J.
(1995) *J Virol* 69, 5723-33.
 43. Wu, L., Gerard, N. P., Wyatt, R., Choe, H., Parolin, C., Ruffing, N.,
15 Borsetti, A., Cardoso, A. A., Desjardin, E., Newman, W., Gerard, C. &
Sodroski, J. (1996) *Nature* 384, 179-83.
 44. Zwick, M. B., Wang, M., Poignard, P., Stiegler, G., Katinger, H., Burton,
D. R. & Parren, P. W. (2001) *J Virol* 75, 12198-208.
 45. McKeating, J. A., Gow, J., Goudsmit, J., Pearl, L. H., Mulder, C. & Weiss,
20 R. A. (1989) *Aids* 3, 777-84.
 46. Arendrup, M., Nielsen, C., Hansen, J. E., Pedersen, C., Mathiesen, L. &
Nielsen, J. O. (1992) *J Acquir Immune Defic Syndr* 5, 303-7.
 47. Kilby, J. M., Hopkins, S., Venetta, T. M., DiMassimo, B., Cloud, G. A.,
Lee, J. Y., Alldredge, L., Hunter, E., Lambert, D., Bolognesi, D., Matthews, T.,
25 Johnson, M. R., Nowak, M. A., Shaw, G. M. & Saag, M. S. (1998) *Nat Med* 4,
1302-7.
 48. Ferrer, M., Kapoor, T. M., Strassmaier, T., Weissenhorn, W., Skehel, J. J.,
Oprian, D., Schreiber, S. L., Wiley, D. C. & Harrison, S. C. (1999) *Nat Struct*
Biol 6, 953-60.
-

49. Bewley, C. A., Louis, J. M., Ghirlando, R. & Clore, G. M. (2002) *J. Biol. Chem.* 277,14238-14245. 25
50. Chan, D. C., Chutkowski, C. T. & Kim, P. S. (1998) *Proc Natl Acad Sci U S A* 95, 15613-7.
- 5 51. Kilby, J. M., Hopkins, S., Venetta, T. M., DiMassimo, B., Cloud, G. A., Lee, J. Y., Alldredge, L., Hunter, E., Lambert, D., Bolognesi, D., Matthews, T., Johnson, M. R., Nowak, M. A., Shaw, G. M. & Saag, M. S. (1998) *Nat Med* 4, 1302-7.
- 10 52. Zollner, B., Feucht, H. H., Schroter, M., Schafer, P., Plettenberg, A., Stoehr, A. & Laufs, R. (2001) *Aids* 15, 935-6.
53. Rizzuto, C. & Sodroski, J. (2000) *AIDS Res Hum Retroviruses* 16, 741-9

Table 1

B1	CACCUACUAGACCACUUUUUGAGCCGGUUUUUUCGGG AACUUGCCAA
B3	GACCGGUGUGUCCUGAUCCAACUGCCACAAGUACCAU AUGCAGGUGACGU
B4	GAGCGGUUAAAGGGAGAUUUAGGCAGCAGCUUGGACA GUGUAUCGGCUGAG
B5	GGGCGCUUAAUGUAUGCCGU AUGACCCUCAACAUCCG ACUCAGUUAAGC
B9	CCUCUUGCACCGCCGAGAAUAUAUUAAGAGGUCCA CAACUAAUUAAG
B11	CCAAGGGCUAAGUCCGCAAAUAUCCUUCUUAAGGAC UCGUUAACGUCGG
B19	AGACCUUAUACCUAGAUUACACGCUCUUCGAGCACG UCGAC
B28	GCGAAACUCCGAUUUCCUCUGUAGUGAUGGGAUUU UCCCCGCCUGAAC
B30	CACCUACCUAAUUAUUAACUUUGGGCAGUAUCCCGC UUUGCUUCUUAUC
B31	GUUUAUAUACACAGGUUAAGCGUAACUUCGCUGGA CAGCAAGAAUCCU
B33	CAUUGGCCAAUUCUUGAAUUCUGACUGCUCGGUAGA AUAGA CCUUAACCA
B36	AGGAGAAUUAUGAGCGGGACAACUUCGUUCCGUGUUC GCGU ACUGAGCGC
B38	CUUCUCCUUGAGGGCCCAUGACCUGACUGUAGAU UCUGCCCUCCGAG
B40	UGUGGGCCACGCCCGAUUUUACGCUUUUACCCGCACG CGAUUGGUUUUGUU
B44	CAGUCGUCAUGGUUAUAGCUGGCCACAACCUCCGUCCU GUCUUAACGGCC
B45	GUCAAGUGCACACCCUUGCUCGUUUUCGAUCGCCAC AACCGAUUCCAAG
B55	CUUGCCGUAGACCCAUUUUCCAUAUCAAGUCACGCG UCUCAAGCUGUUA
B62	CCCGUACCAACACCCUAUGCACAUCGUUGUUUGUC GUCUUUCCCGCAU
B81	AGUUUCAUCGUCCGAGCAAGAUAUCCUA AUGGCGUCCGG CGCGUUUAUGACU

B82 CCCC AUGG CACGCC GAUCAG UUUUGCUG UCCGCCG GUCCA UAAUA CU
B84 AUGAC GUACCC GCACA AGCCAC CACAAG UCUA AUUCG CGCCAC CCUUGC
B86 ACGUG CUCUA UCUUUA AUUCG UGGGCU CUGCGGCU AGCCUC UUAGCUC
B114 CAUUA CAGCGA AGUUA CCAGCA UACAGG UACAAU GCGCCC GACUAGU
B116 GACGG CAACCC GUUAUA ACCUCC ACUGGC UAUCCCG UUAAGCUU CCCCUA
B132 UCACC UGUACA CUACCU CUACCA UGCUUG AGCCUA CG CCGC CGACAC CC
B136 CGUAU UCAUCAGG UAGCGU AGAUCC GUUGUG GCGGGCU GUUC CAUUUUA
B137 GCCAG GGUUCA UCAUUC ACGGCC GAUUUC GAAGCUC CUAACUCG AGACAC.

CLAIMS

1. A nucleic acid molecule capable of binding to an envelope glycoprotein of an enveloped virus, and neutralising said virus.

5

2. A nucleic acid molecule as claimed in claim 1, wherein said virus is HIV.

10

3. A nucleic acid molecule as claimed in claim 1 or claim 2, wherein said virus is HIV-1.

4. A nucleic acid molecule as claimed in any one of claims 1 to 3, wherein the envelope glycoprotein is gp120.

15

5. A nucleic acid molecule as claimed in any one of claims 1 to 4, wherein said nucleic acid molecule is selected from those listed in Table 1.

6. A nucleic acid molecule as claimed in any one of claims 1-5, wherein said nucleic acid molecule comprises modified nucleotides.

20

7. A nucleic acid molecule as claimed in claim 6, wherein said modified bases are modified by any one or more of the following means:

(i) pyrimidine 6 or 8 position, or purine 5 modification with I, Br, Cl, CH₃ ;

25

(ii) pyrimidine 2 position modification with NH₃;

(iii) pyrimidine modifications O⁶-CH₃, N⁶-CH₃ and N²-CH₃;

(iv) 2' sugar modifications;

(v) 3' and/or 5' capping

8. A method for screening for potential therapeutic targets utilising the nucleic acid molecule as defined in any one of claims 1 to 7.

5 9. A method as claimed in claim 8, wherein said method involves competitive inhibition.

10 10. A pharmaceutical composition comprising at least one nucleic acid molecule as claimed in any one of claims 1-7, optionally together with one or more pharmaceutically acceptable carriers, diluents or excipients.

11. The use of a nucleic acid molecule as defined in any one of claims 1-7 in the manufacture of a medicament for use in the treatment of HIV infection.

Figure 1





Figure 2




Figure 3

A

```

      10      20      30      40      50      60      70      80
(M68893) MRVTEIRKSYQHWRWGIMLLGILMICNAEEKLWVTVYYGVPVWKEATTLFCASDRKAYDTEVHNVWATHACVPTDFNP
(NIH510*) .....A.....
clone1  -----X.....M.....A.....
clone2  -----X.....M.....A.....
clone3  -----X.....A.....
clone4  -----A.....

      ← → gp120 start
      90      100      110      120      130      140      150      160
(M68893) QEVELKNVTENFNMWKNMVEQMHEDIISLWDQSLKPCVKLTPLCVTLNCTDLRNATNGNDTNTTSSSRGMVGGGEMKNC
(NIH510*) .....C.....SR.V.....
clone1  .....C.....SR.V.....
clone2  .....S.....V.....
clone3  .....S.....
clone4  .....S.....


      170      180      190      200      210      220      230      240
(M68893) SFNITTNIRGKVQKEYALFYKLDIAPIDNNSNNRYRLISCVITQACPKVSFEPIPIHYCAPAGFAILKCKDKKFNGK
(NIH510*) .....E...V.....
clone1  .....G.....E...V...KIDXX.....E.....
clone2  .....E...V.....
clone3  .....G.....E...V...KIDXX.....
clone4  .....G.....E...V...KIDXX.....

      ~ 250      260      270      280      290      300      310      320
(M68893) GPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEVVIRSANFADNAKVIIIVQLNESVEINCTRPNNNTRKSIHIGPGRAFV
(NIH510*) .....S.....E..TN...T.....
clone1  .....S.....E..TN...T.....
clone2  .....S.....E..TN...T.....
clone3  .....S.....E..TN...T.....
clone4  .....S.....E..TN...T.....

      V3 end ←
      330      340      350      360      370      380      390      400
(M68893) TTGEIIGDIRQAHCNLSRAKWNNTLNKIVIKLREQFGNKTIVFKHSSGGDPEIVTHSFNCGGEFFYCNSSTQLFNSTWNVT
(NIH510*) .....Y.....
clone1  .....Y.....
clone2  .....
clone3  .....
clone4  .....

      410      420      430      440      450      460      470      480
(M68893) EESNNTVENNTITLPCRIKQIINMWQEVGRAMYAPPPIRGQIRCSSNITGLLLTRDGGPEDNKTEVFRPGGGDMRDNRSE
(NIH510*) .....K.....
clone1  .....K.....
clone2  .....K.....
clone3  .....K.....
clone4  .....K.....
```

B



C






Figure 4



PCT Application
GB0304897



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.